- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
As the global economy mends, the 2021 growth of Duchenne Muscular Dystrophy will have significant change from previous year. According to our latest study, the global Duchenne Muscular Dystrophy market size is USD million in 2022 from USD 1176.8 million in 2021, with a change of % between 2021 and 2022. The global Duchenne Muscular Dystrophy market size will reach USD 14870 million in 2028, growing at a CAGR of 43.7% over the analysis period.
The United States Duchenne Muscular Dystrophy market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Duchenne Muscular Dystrophy market, reaching US$ million by the year 2028. As for the Europe Duchenne Muscular Dystrophy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Duchenne Muscular Dystrophy players cover Sarepta Therapeutics, PTC Therapeutics, Pfizer, and Bristol-Myers Squibb, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Exondys 51
Emflaza
Translarna
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospitals
Clinics
Home Care
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Duchenne Muscular Dystrophy by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy by Country/Region, 2017, 2022 & 2028
2.2 Duchenne Muscular Dystrophy Segment by Type
2.2.1 Exondys 51
2.2.2 Emflaza
2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy Sales by Type
2.3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2017-2022)
2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2017-2022)
2.4 Duchenne Muscular Dystrophy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Sales by Application
2.5.1 Global Duchenne Muscular Dystrophy Sale Market Share by Application (2017-2022)
2.5.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Application (2017-2022)
2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2017-2022)
3 Global Duchenne Muscular Dystrophy by Company
3.1 Global Duchenne Muscular Dystrophy Breakdown Data by Company
3.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Company (2020-2022)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2022)
3.2 Global Duchenne Muscular Dystrophy Annual Revenue by Company (2020-2022)
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2022)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2022)
3.3 Global Duchenne Muscular Dystrophy Sale Price by Company
3.4 Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Duchenne Muscular Dystrophy Product Location Distribution
3.4.2 Players Duchenne Muscular Dystrophy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Duchenne Muscular Dystrophy by Geographic Region
4.1 World Historic Duchenne Muscular Dystrophy Market Size by Geographic Region (2017-2022)
4.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Duchenne Muscular Dystrophy Annual Revenue by Geographic Region
4.2 World Historic Duchenne Muscular Dystrophy Market Size by Country/Region (2017-2022)
4.2.1 Global Duchenne Muscular Dystrophy Annual Sales by Country/Region (2017-2022)
4.2.2 Global Duchenne Muscular Dystrophy Annual Revenue by Country/Region
4.3 Americas Duchenne Muscular Dystrophy Sales Growth
4.4 APAC Duchenne Muscular Dystrophy Sales Growth
4.5 Europe Duchenne Muscular Dystrophy Sales Growth
4.6 Middle East & Africa Duchenne Muscular Dystrophy Sales Growth
5 Americas
5.1 Americas Duchenne Muscular Dystrophy Sales by Country
5.1.1 Americas Duchenne Muscular Dystrophy Sales by Country (2017-2022)
5.1.2 Americas Duchenne Muscular Dystrophy Revenue by Country (2017-2022)
5.2 Americas Duchenne Muscular Dystrophy Sales by Type
5.3 Americas Duchenne Muscular Dystrophy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Sales by Region
6.1.1 APAC Duchenne Muscular Dystrophy Sales by Region (2017-2022)
6.1.2 APAC Duchenne Muscular Dystrophy Revenue by Region (2017-2022)
6.2 APAC Duchenne Muscular Dystrophy Sales by Type
6.3 APAC Duchenne Muscular Dystrophy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Duchenne Muscular Dystrophy by Country
7.1.1 Europe Duchenne Muscular Dystrophy Sales by Country (2017-2022)
7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2022)
7.2 Europe Duchenne Muscular Dystrophy Sales by Type
7.3 Europe Duchenne Muscular Dystrophy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Duchenne Muscular Dystrophy by Country
8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2017-2022)
8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2022)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Sales by Type
8.3 Middle East & Africa Duchenne Muscular Dystrophy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy
10.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy
10.4 Industry Chain Structure of Duchenne Muscular Dystrophy
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Duchenne Muscular Dystrophy Distributors
11.3 Duchenne Muscular Dystrophy Customer
12 World Forecast Review for Duchenne Muscular Dystrophy by Geographic Region
12.1 Global Duchenne Muscular Dystrophy Market Size Forecast by Region
12.1.1 Global Duchenne Muscular Dystrophy Forecast by Region (2023-2028)
12.1.2 Global Duchenne Muscular Dystrophy Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Duchenne Muscular Dystrophy Forecast by Type
12.7 Global Duchenne Muscular Dystrophy Forecast by Application
13 Key Players Analysis
13.1 Sarepta Therapeutics
13.1.1 Sarepta Therapeutics Company Information
13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Offered
13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sarepta Therapeutics Main Business Overview
13.1.5 Sarepta Therapeutics Latest Developments
13.2 PTC Therapeutics
13.2.1 PTC Therapeutics Company Information
13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Offered
13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 PTC Therapeutics Main Business Overview
13.2.5 PTC Therapeutics Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Duchenne Muscular Dystrophy Product Offered
13.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Offered
13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Italfarmaco
13.5.1 Italfarmaco Company Information
13.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Offered
13.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Italfarmaco Main Business Overview
13.5.5 Italfarmaco Latest Developments
13.6 Santhera Pharmaceuticals
13.6.1 Santhera Pharmaceuticals Company Information
13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Offered
13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Santhera Pharmaceuticals Main Business Overview
13.6.5 Santhera Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Duchenne Muscular Dystrophy Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Duchenne Muscular Dystrophy Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Exondys 51
Table 4. Major Players of Emflaza
Table 5. Major Players of Translarna
Table 6. Global Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 7. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Table 8. Global Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & ($ million)
Table 9. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2022)
Table 10. Global Duchenne Muscular Dystrophy Sale Price by Type (2017-2022) & (USD/Dose)
Table 11. Global Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 12. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Table 13. Global Duchenne Muscular Dystrophy Revenue by Application (2017-2022)
Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2022)
Table 15. Global Duchenne Muscular Dystrophy Sale Price by Application (2017-2022) & (USD/Dose)
Table 16. Global Duchenne Muscular Dystrophy Sales by Company (2020-2022) & (K Doses)
Table 17. Global Duchenne Muscular Dystrophy Sales Market Share by Company (2020-2022)
Table 18. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2022)
Table 20. Global Duchenne Muscular Dystrophy Sale Price by Company (2020-2022) & (USD/Dose)
Table 21. Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution and Sales Area
Table 22. Players Duchenne Muscular Dystrophy Products Offered
Table 23. Duchenne Muscular Dystrophy Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Duchenne Muscular Dystrophy Sales by Geographic Region (2017-2022) & (K Doses)
Table 27. Global Duchenne Muscular Dystrophy Sales Market Share Geographic Region (2017-2022)
Table 28. Global Duchenne Muscular Dystrophy Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Duchenne Muscular Dystrophy Sales by Country/Region (2017-2022) & (K Doses)
Table 31. Global Duchenne Muscular Dystrophy Sales Market Share by Country/Region (2017-2022)
Table 32. Global Duchenne Muscular Dystrophy Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Duchenne Muscular Dystrophy Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 35. Americas Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2022)
Table 36. Americas Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2022)
Table 38. Americas Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 39. Americas Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Table 40. Americas Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 41. Americas Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Table 42. APAC Duchenne Muscular Dystrophy Sales by Region (2017-2022) & (K Doses)
Table 43. APAC Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2022)
Table 44. APAC Duchenne Muscular Dystrophy Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Duchenne Muscular Dystrophy Revenue Market Share by Region (2017-2022)
Table 46. APAC Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 47. APAC Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Table 48. APAC Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 49. APAC Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Table 50. Europe Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 51. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2022)
Table 52. Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2022)
Table 54. Europe Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 55. Europe Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Table 56. Europe Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 57. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 59. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 63. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 65. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy
Table 67. Key Market Challenges & Risks of Duchenne Muscular Dystrophy
Table 68. Key Industry Trends of Duchenne Muscular Dystrophy
Table 69. Duchenne Muscular Dystrophy Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Duchenne Muscular Dystrophy Distributors List
Table 72. Duchenne Muscular Dystrophy Customer List
Table 73. Global Duchenne Muscular Dystrophy Sales Forecast by Region (2023-2028) & (K Doses)
Table 74. Global Duchenne Muscular Dystrophy Sales Market Forecast by Region
Table 75. Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Duchenne Muscular Dystrophy Sales Forecast by Country (2023-2028) & (K Doses)
Table 78. Americas Duchenne Muscular Dystrophy Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Duchenne Muscular Dystrophy Sales Forecast by Region (2023-2028) & (K Doses)
Table 80. APAC Duchenne Muscular Dystrophy Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Duchenne Muscular Dystrophy Sales Forecast by Country (2023-2028) & (K Doses)
Table 82. Europe Duchenne Muscular Dystrophy Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Duchenne Muscular Dystrophy Sales Forecast by Country (2023-2028) & (K Doses)
Table 84. Middle East & Africa Duchenne Muscular Dystrophy Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Duchenne Muscular Dystrophy Sales Forecast by Type (2023-2028) & (K Doses)
Table 86. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Duchenne Muscular Dystrophy Sales Forecast by Application (2023-2028) & (K Doses)
Table 90. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2023-2028)
Table 93. Sarepta Therapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 94. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Offered
Table 95. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 96. Sarepta Therapeutics Main Business
Table 97. Sarepta Therapeutics Latest Developments
Table 98. PTC Therapeutics Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 99. PTC Therapeutics Duchenne Muscular Dystrophy Product Offered
Table 100. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 101. PTC Therapeutics Main Business
Table 102. PTC Therapeutics Latest Developments
Table 103. Pfizer Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 104. Pfizer Duchenne Muscular Dystrophy Product Offered
Table 105. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 106. Pfizer Main Business
Table 107. Pfizer Latest Developments
Table 108. Bristol-Myers Squibb Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 109. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Offered
Table 110. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 111. Bristol-Myers Squibb Main Business
Table 112. Bristol-Myers Squibb Latest Developments
Table 113. Italfarmaco Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 114. Italfarmaco Duchenne Muscular Dystrophy Product Offered
Table 115. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 116. Italfarmaco Main Business
Table 117. Italfarmaco Latest Developments
Table 118. Santhera Pharmaceuticals Basic Information, Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 119. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Offered
Table 120. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 121. Santhera Pharmaceuticals Main Business
Table 122. Santhera Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Duchenne Muscular Dystrophy
Figure 2. Duchenne Muscular Dystrophy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Duchenne Muscular Dystrophy Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Duchenne Muscular Dystrophy Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Duchenne Muscular Dystrophy Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Exondys 51
Figure 10. Product Picture of Emflaza
Figure 11. Product Picture of Translarna
Figure 12. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2021
Figure 13. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2022)
Figure 14. Duchenne Muscular Dystrophy Consumed in Hospitals
Figure 15. Global Duchenne Muscular Dystrophy Market: Hospitals (2017-2022) & (K Doses)
Figure 16. Duchenne Muscular Dystrophy Consumed in Clinics
Figure 17. Global Duchenne Muscular Dystrophy Market: Clinics (2017-2022) & (K Doses)
Figure 18. Duchenne Muscular Dystrophy Consumed in Home Care
Figure 19. Global Duchenne Muscular Dystrophy Market: Home Care (2017-2022) & (K Doses)
Figure 20. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 21. Global Duchenne Muscular Dystrophy Revenue Market Share by Application in 2021
Figure 22. Duchenne Muscular Dystrophy Revenue Market by Company in 2021 ($ Million)
Figure 23. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2021
Figure 24. Global Duchenne Muscular Dystrophy Sales Market Share by Geographic Region (2017-2022)
Figure 25. Global Duchenne Muscular Dystrophy Revenue Market Share by Geographic Region in 2021
Figure 26. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2022)
Figure 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Country/Region in 2021
Figure 28. Americas Duchenne Muscular Dystrophy Sales 2017-2022 (K Doses)
Figure 29. Americas Duchenne Muscular Dystrophy Revenue 2017-2022 ($ Millions)
Figure 30. APAC Duchenne Muscular Dystrophy Sales 2017-2022 (K Doses)
Figure 31. APAC Duchenne Muscular Dystrophy Revenue 2017-2022 ($ Millions)
Figure 32. Europe Duchenne Muscular Dystrophy Sales 2017-2022 (K Doses)
Figure 33. Europe Duchenne Muscular Dystrophy Revenue 2017-2022 ($ Millions)
Figure 34. Middle East & Africa Duchenne Muscular Dystrophy Sales 2017-2022 (K Doses)
Figure 35. Middle East & Africa Duchenne Muscular Dystrophy Revenue 2017-2022 ($ Millions)
Figure 36. Americas Duchenne Muscular Dystrophy Sales Market Share by Country in 2021
Figure 37. Americas Duchenne Muscular Dystrophy Revenue Market Share by Country in 2021
Figure 38. United States Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 39. Canada Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 40. Mexico Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 41. Brazil Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 42. APAC Duchenne Muscular Dystrophy Sales Market Share by Region in 2021
Figure 43. APAC Duchenne Muscular Dystrophy Revenue Market Share by Regions in 2021
Figure 44. China Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 45. Japan Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 46. South Korea Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 47. Southeast Asia Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 48. India Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 49. Australia Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 50. Europe Duchenne Muscular Dystrophy Sales Market Share by Country in 2021
Figure 51. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country in 2021
Figure 52. Germany Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 53. France Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 54. UK Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 55. Italy Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 56. Russia Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 57. Middle East & Africa Duchenne Muscular Dystrophy Sales Market Share by Country in 2021
Figure 58. Middle East & Africa Duchenne Muscular Dystrophy Revenue Market Share by Country in 2021
Figure 59. Egypt Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 60. South Africa Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 61. Israel Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 62. Turkey Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 63. GCC Country Duchenne Muscular Dystrophy Revenue Growth 2017-2022 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy in 2021
Figure 65. Manufacturing Process Analysis of Duchenne Muscular Dystrophy
Figure 66. Industry Chain Structure of Duchenne Muscular Dystrophy
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Please feel free to write an email to us or to use our electronic ticketing system.
